Primary myelofibrosis is an uncommon disease, with an annual incidence of approximately 0.5-1.5 cases per 100,000 individuals in the United States. The median length of survival for patients with primary myelofibrosis is 3.5-5.5 years. The 5-year survival rate is about half of that expected for age- and sex-matched controls. Fewer than 20% of patients are expected to be alive at 10 years. The common causes of death in patients with primary myelofibrosis are infections, hemorrhage, cardiac failure, post-splenectomy mortality, and transformation into acute leukemia. Leukemic transformation occurs in approximately 20% of patients with primary myelofibrosis within the first 10 years.
Comprehensive insight on patient segmentation based on age, sex, types (Primary Myelofibrosis, Secondary Myelofibrosis) and progression of Polycythemia Vera (PV), Essential Thrombocythemia (ET) into MF. Biomarker: (JAK2 (Janus Kinase 2)-V617F, CALR (Calreticulin-R), MPL (Myeloproliferative Leukaemia virus gene MPL515L/K and others). Signs & Symptoms, Clinical Manifestations, Treatment types have been provided in the epidemiology section of the MYELOFIBROSIS and its treatment in the 8 MM coun-tries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
In terms of pharmacologic therapies, there are few drug candidates are in different Phase (Phase I, II & III) stages of development. Key companies are, Pharmaxis Ltd: PXS-5505, Incyte Corpo-ration: Ruxolitinib, Celgene: Fedratinib, AbbVie: Ruxolitinib Navi-toclax, NS Pharma, Inc.:NS-018, Sumitomo Dainippon Pharma Oncology: TP-3654, Sierra Oncology: Momelotinib, CTI BioPharma: Pacritinib, Imago BioSciences: IMG-7289, Samus Therapeutics, PU-H71, Constellation Pharmaceuticals: CPI-0610. Looking at the current clinical development and assets progress card, it would really be a great opportunity for the pharmaceutical company to build products around the treatment of MYELOFI-BROSIS specifically for moderate to severe patients. Therapies that target other pathways that may be abnormally activated in MF are also being tested. LCL-161 is an oral therapy that blocks the activity of an inhibitor of apoptosis (IAP) proteins, which promote cell survival. SL-401 is a therapy that targets the IL-3 receptor, which is found on the surface of MF cells.
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,